BioMarin Pharma (BMRN) Announces EMA Validates its MAA for Valoctocogene Roxaparvovec to Treat Severe Hemophilia A
Go back to BioMarin Pharma (BMRN) Announces EMA Validates its MAA for Valoctocogene Roxaparvovec to Treat Severe Hemophilia A| BioMarin Pharmaceuticals, Inc. (NASDAQ: BMRN) | Delayed: 92.06 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $92.06 | 52 Week High | $108.96 | |||
| Open | $92.06 | 52 Week Low | $62.12 | |||
| Day High | $92.06 | P/E | N/A | |||
| Day Low | $92.06 | EPS | $-1.27 | |||
| Volume | 97 | |||||
